Why Is Pediatric-Cancer Focused OS Therapies Stock Trading Higher On Wednesday?

On Wednesday, OS Therapies, Inc. OSTX revealed data from a Phase 2b trial of OST-HER2 (OST31-164), a HER2-targeted immunotherapy candidate in the rare pediatric-designated indication of prevention of recurrent, fully resected, lung metastatic osteosarcoma, a rare, cancerous bone tumor that develops in bone-forming cells.The data demonstrate statistically significant results in the primary endpoint of the study, 12-month event-free survival (EFS), where an event is defined as the recurrence of metastatic ost ...